Brainstorm Cell Therapeutics Email Format

Biotechnology ResearchCentral District, Israel11-50 Employees

BrainStorm Cell Therapeutics is a biotechnology research company based in Petah Tiqwa, Israel, with 11-50 employees, focused on developing autologous stem cell therapies for neurodegenerative diseases. Its lead candidate, NurOwn, differentiates a patient’s own mesenchymal stem cells into neurotrophic factor–secreting cells that are transplanted at or near the affected tissue to act as a living drug delivery system for neurotrophic factors. The company reports proof-of-concept in multiple animal models of neurodegenerative diseases, including Parkinson’s, Huntington’s, ALS, MS, and peripheral nerve injury, and has completed two single-arm ALS trials in Israel showing good safety and tolerability with signals of efficacy. It completed a Phase 3 randomized, double-blind, placebo-controlled trial across multiple US sites with external grants and is planning a Phase 3b ALS study under FDA Special Protocol Assessment. In 2026 NurOwn received Orphan Drug designation from both the U.S. FDA and the European Medicines Agency, reflecting its focus on unmet medical needs in neurodegenerative diseases.

Get verified Brainstorm Cell Therapeutics emails free

Company overview Employee directory